Bowe A, Hayes M, John I, Diaz M, et al. Glucagon-like peptide-1 receptor agonist versus sodium-glucose cotransporter-2 inhibitor persistence in Medicare Advantage beneficiaries with type 2 diabetes, cardiovascular risk, and obesity. Diabetes Obes Metab 2025 Oct 30. doi: 10.1111/dom.70219.
PMID: 41165079